A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will
assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with
advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in
cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and
tolerability of SB939 in combination with standard azacitidine therapy.